Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin)
Related Experiment Video
Updated: Aug 10, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
P R Hearn1, C L Reynolds, K Johansen
1Department of Biological Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Abstract:
Two patients with Cushing's syndrome due to lung carcinoid tumours were given the long-acting somatostatin analogue SMS 201-995 (Sandostatin). One received a single 50 micrograms dose which produced a 50% reduction in circulating ACTH levels within 4 h. The other has been maintained in clinical and biochemical remission for 10 weeks on 100 micrograms tid. This is the first report of the successful use of SMS 201-995 in carcinoid-induced Cushing's syndrome, and suggests that this hormone analogue could be valuable in the long term medical management of such patients.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome I: Introduction
Cushing Syndrome II: Pathophysiology

